Last reviewed · How we verify
Omaveloxolone Capsules, 150 mg
At a glance
| Generic name | Omaveloxolone Capsules, 150 mg |
|---|---|
| Also known as | RTA 408 capsules, 150 mg |
| Sponsor | Biogen |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Fatigue
- Upper respiratory tract infection
- Abdominal pain
- Constipation
- Gastrooesophageal reflux disease
- Vomiting
- Excoriation
- Thermal burn
- Alanine aminotransferase increased
- Aspartate aminotransferase increased
- Blood pressure increased
- Arthralgia
Key clinical trials
- A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia (PHASE2)
- A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old (PHASE1)
- Efficacy of Omaveloxolone Treatment for Dysphagia in French Patients With Friedreich's Ataxia
- RTA 408 Capsules in Patients With Melanoma - REVEAL (PHASE1, PHASE2)
- A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone (PHASE1)
- A Human AME Study for Omaveloxolone (PHASE1)
- A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function (PHASE1)
- A Pharmacokinetic Study of Omaveloxolone in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Omaveloxolone Capsules, 150 mg CI brief — competitive landscape report
- Omaveloxolone Capsules, 150 mg updates RSS · CI watch RSS
- Biogen portfolio CI